Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smart brain stimulator adjusts on the fly to help Parkinson's patients walk better

NCT ID NCT07424508

Disease control Sponsor: Doris Wang, MD, PhD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new way to use deep brain stimulation (DBS) for Parkinson's disease. Instead of constant stimulation, the device automatically switches settings when the person starts walking, aiming to improve gait and balance. Six people who already have a special DBS implant will try this adaptive approach and be compared to standard open-loop stimulation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deep brain stimulation device (Summit RC+S)
What this could lead to
If it works, this could lead to a smarter DBS system that automatically adjusts stimulation to improve walking and reduce freezing in Parkinson's disease.
What could go wrong
This is a very early, tiny study with only 6 participants, so results may not apply to everyone. The device is investigational and not yet proven safe or effective for this use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Apr 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ability to give informed consent for the study * Subjects implanted with Summit RC+S investigational DBS system. * Absence of significant cognitive impairment (score of 21 or greater on the Montreal Cognitive Assessment (MoCA) * Signed informed consent * Age 21-75 * Diagnosis of idiopathic PD with duration of motor symptoms for 3 years or greater * Patient has undergone appropriate therapy with oral medications with inadequate relief as determined by a movement disorders neurologist. * UPDRS-III score off medication between 20 and 80 and an improvement of at least 30% in the baseline UPDRS-III on medication score, compared to the baseline off-medication score, and motor fluctuations with at least 2 hours per day of on time without dyskinesia or with non-bothersome dyskinesia. OR Patients with tremor-dominant PD (a tremor score of at least 2 on a UPDRS-III sub-score for tremor), treatment resistant, with significant functional disability despite maximal medical management * Patients with gait impairments: slowed gait, shuffling steps, postural instability, or freezing of gait off medication. Exclusion Criteria: * Inability to comply with study procedures * Patients who cannot walk (wheelchair bound)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease (PD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCSF

    San Francisco, California, 94134, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.